From two of our previous studies, we also reported that using the glucagon-like peptide-1 receptor (GLP-1R) agonist, liraglutide, which is widely applied in diabetes therapeutics, could prevent and reverse monocrotaline (MCT)-induced PAH by suppressing ET-1 and enhancing the eNOS/sGC/PKG pathways [37]. Here, GLP1R is linked to diabetes mellitus.